Selvas Healthcare , an affiliate of Selvas AI, announced on the 11th that it will participate as a partner organization in the '2025 2nd Korean ARPA-H Project' hosted by Chungnam National University Hospital.
This project, a mission-driven R&D initiative spearheaded by the Ministry of Health and Welfare and the Korea Health Industry Development Institute, focuses on developing wearable and AI-based healthcare technologies for early detection and prevention of acute exacerbations of chronic kidney disease. The project duration is four years and six months, with a total budget of up to KRW 12.75 billion.
Selvas Healthcare plans to participate as a partner organization, conduct clinical trials utilizing its commercialized devices, and develop a market entry and phased commercialization strategy for the platform. Through this project, the company aims to verify the commercial viability of an integrated chronic disease management system applicable to actual medical settings and expand its portfolio with AI-based platform businesses.
Selvas Healthcare continues to expand its business in the digital healthcare sector. Recently, "UltraSite AI Guidance," a cardiac ultrasound AI guidance software developed through Selvas InVision, a joint venture with UltraSite, received domestic Class 2 digital medical device certification. This product features real-time image guidance, making it ideal for use in emergency and telemedicine settings.
Additionally, the KIMES 2025 exhibition unveiled the "AI Senior Healthcare Platform" for chronic disease management in the elderly. This platform integrates Selvas AI's disease onset prediction service, "Selvy Checkup," allowing users to measure blood pressure, body composition, and blood sugar levels to predict disease onset.
A Selvas Healthcare official stated, “Through this R&D project, we expect to be able to expand our business area from the existing healthcare device-centered business model to one centered on AI-based digital platforms.” They added, “Based on verification in clinical settings, we will review the commercialization potential of the platform and strengthen our competitiveness in the digital healthcare market.”
- See more related articles
You must be logged in to post a comment.